LIVE WEBINARS: July 31, August 7 and August 14, 2020, 9:00 AM – 10:00 AM ET

Virtual Molecular Tumor Board: Optimizing Biomarker-Based Decision-Making for Patients with Solid Tumors

A CME Webinar Series

To aid clinicians in understanding the various interpretations and applications of next-generation sequencing/multiplex testing and other diagnostic advances, many institutions have implemented molecular tumor boards, which include both medical oncologists and pathologists. The major focus of these more recently established collaborative forums is to assist clinicians as they attempt to apply molecular profiling results and offer best-practice care for their patients. We are pleased to announce that we will be recreating this dynamic virtually by hosting a 3-part webinar series to explore the rapidly evolving role of biomarker assessment and targeted therapy for patients with solid tumors.

We hope you will join us for one or more of these informative sessions.

Faculty

Bryan P Schneider, MD
The Vera Bradley Professor of Oncology
Director of the IU Health Precision Genomics Program
Indiana University Melvin and
Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana

Milan Radovich, PhD
Associate Professor
IU Health Vice President for Oncology Genomics
Indiana University Melvin and
Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana

Moderator

Neil Love, MD
Research To Practice
Miami, Florida

Schedule of Events

There is no registration fee for these events.

31
JULY
Role of Genomic Profiling for Patients with Solid Tumors and the
Optimal Application of Available Testing Platforms
Andrew McKenzie, PhD
Director, Personalized Medicine
Sarah Cannon Research Institute
Nashville, Tennessee
Friday | 9:00 AM – 10:00 AM Eastern Time | Webinar
7
AUG
Identification of New and Emerging Genomic Alterations in
Metastatic Non-Small Cell Lung Cancer
Alexander E Drilon, MD
Chief, Early Drug Development Service
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Andrew McKenzie, PhD
Director, Personalized Medicine
Sarah Cannon Research Institute
Nashville, Tennessee
Friday | 9:00 AM – 10:00 AM Eastern Time | Webinar
14
AUG
Recognition and Management of Targetable Tumor Mutations
in Less Common Cancer Types
Marcia S Brose, MD, PhD
Professor
Director, Center for Rare Cancers and Personalized Therapy
Abramson Cancer Center
Department of Medicine, Division of Hematology/Oncology
Department of Otorhinolaryngology: Head and Neck Surgery
Philadelphia, Pennsylvania
Andrew McKenzie, PhD
Director, Personalized Medicine
Sarah Cannon Research Institute
Nashville, Tennessee
Friday | 9:00 AM – 10:00 AM Eastern Time | Webinar

Complimentary Registration
A link to the event will be provided after registration via an email confirmation.

A full library of presentation slides will also be made available for those who participate in these webinars.


Supporter
These activities are supported by an educational grant from Lilly.

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, pathologists and other allied healthcare professionals involved in the treatment of lung cancer and other solid tumors.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Recognize the spectrum and prevalence of potentially targetable genomic alterations across various solid tumor types and the means by which these alterations contribute to tumor growth and proliferation.
  • Recall FDA-approved and guideline-endorsed biomarker-testing platforms for patients with advanced solid tumors.
  • Refine clinical testing algorithms in practice by assessing the advantages and limitations of available assays, including their capacity to accurately identify various genomic abnormalities.
  • Recall new and emerging biomarkers for treatment (eg, RET fusions, MET exon 14 mutations, KRAS G12C mutations) in metastatic non-small cell lung cancer (NSCLC), and develop an understanding of available and investigational therapies that might benefit patients harboring each of these abnormalities.
  • Identify patients with NSCLC appropriate for targeted therapeutic interventions by assessing the correlation between response to specific agents and the presence of established and emerging genomic alterations.
  • Explore available data on established and investigational tumor driver mutations and the clinical activity of biomarker-based treatments in less-common tumor types (eg, thyroid cancer, cholangiocarcinoma).
  • Appraise available safety and efficacy results with the novel RET inhibitor selpercatinib in patients with RET-driven NSCLC or thyroid cancer in preparation for the potential nonresearch availability of this novel compound.
  • Integrate available and emerging novel therapies that are based on genomic analyses into the care of patients with various solid tumors.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in each activity.

American Board of Internal Medicine (ABIM) and American Board of Pathology (ABPath) — Maintenance of Certification (MOC)

ABIM MOC Credit

Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

ABPath MOC Credit

Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Self-Assessment credit (SAM) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath credit.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDrs McKenzie and Schneider have no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr BroseConsulting Agreements and Contracted Research: Blueprint Medicines, Exelixis Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Dr DrilonAdvisory Committee and Consulting Agreements: AbbVie Inc, ArcherDX Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, BerGenBio ASA, Blueprint Medicines, Elevation Oncology, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Ignyta Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Medendi Inc, MJH Life Sciences, Monopteros Therapeutics, MORE Health Inc, Novartis, Pfizer Inc, Remedica Ltd, Roche Laboratories Inc, Takeda Oncology, TP Therapeutics Inc, Tyra Biosciences, Verastem Inc; Contracted Research: Exelixis Inc, Foundation Medicine, GlaxoSmithKline, Pfizer Inc, PharmaMar, Taiho Oncology Inc, Teva Oncology; Food and Beverage: Merck, Puma Biotechnology Inc; Royalties: Wolters Kluwer; Other: Boehringer Ingelheim Pharmaceuticals Inc, Merus BV. Dr RadovichContracted Research: Boston Biomedical Inc, Lilly; Ownership Interest: Immunomedics Inc, LifeOmic Health LLC, Tyme Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
These activities are supported by an educational grant from Lilly.